Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 1988 Mar-Apr;3(2):107-27.
doi: 10.1007/BF03259936.

Adverse reactions and interactions of cyclosporin

Affiliations
Review

Adverse reactions and interactions of cyclosporin

J P Scott et al. Med Toxicol Adverse Drug Exp. 1988 Mar-Apr.

Abstract

Cyclosporin is a potent, widely used specific immunosuppressive agent which affects T-helper cells, and has little myelotoxicity. Its pharmacokinetics are complex and many of its actions remain poorly understood. Numerous side effects have been reported, affecting most organs. Most troublesome have been renal injury, systemic hypertension and vascular changes. Oral use is more effective than intramuscular and safer than the intravenous route. Interactions with other drugs include those which affect hepatic metabolism and those which reduce clearance. Aminoglycosides, macrolide antibiotics, imidazole derivatives, calcium channel blockers, sulphonamides and steroids are included in such interactions. Other metabolic effects of cyclosporin are more subtle and include hyperchloraemic alkalosis, changes in serum potassium and magnesium and effects on testosterone and prolactin levels. Acute poisoning with cyclosporin has been reported, again without myelosuppression. Cyclosporin is an important agent with multisystem toxicity, which requires precise monitoring of drug concentrations, liver and renal function, haemoglobin levels and plasma electrolytes. Cyclosporin pharmacodynamics and interactions with other drugs need to be carefully considered if lower rates of toxicity are to be achieved.

PubMed Disclaimer

References

    1. Klin Wochenschr. 1985 Oct 15;63(20):1081-2 - PubMed
    1. Lancet. 1984 Dec 22;2(8417-8418):1470-1 - PubMed
    1. Am J Med. 1982 Jul 20;73(1A):182-5 - PubMed
    1. Br J Haematol. 1985 Mar;59(3):547-53 - PubMed
    1. Ann Rheum Dis. 1986 Sep;45(9):726-31 - PubMed

LinkOut - more resources